New-generation 5-HT4 receptor agonists: Potential for treatment of gastrointestinal motility disorders

Expert Opinion on Investigational Drugs

Volumn 19, Issue 6, 2010, Pages 765-775

  Manabe, Noriaki ^a   Wong, Banny S ^a   Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

5 HT4; Affinity; Arrhythmia; ATI 7505; Cardiovascular ischemia; Constipation; Dyspepsia; Gastroparesis; Prucalopride; Selectivity; Serotonin; TD 5108; Velusetrag

Indexed keywords

ATI 7505; CISAPRIDE; PLACEBO; PRUCALOPRIDE; SEROTONIN AGONIST; TD 5108; TEGASEROD; UNCLASSIFIED DRUG; VELUSETRAG;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL TRANSIT; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HUMAN; INTESTINE INNERVATION; IRRITABLE COLON; NAUSEA; NONHUMAN; QT INTERVAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH EMPTYING; VASCULAR SMOOTH MUSCLE;

ANIMALS; CLINICAL TRIALS AS TOPIC; COLONIC DISEASES, FUNCTIONAL; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGONISTS;

EID: 77952323991     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.482927     Document Type: Review

References (76)

1. Camilleri M. Serotonergic drugs: emerging therapies for IBS. In: Camilleri M, Spiller RC, editors, Irritable Bowel Syndrome. WB. Saunders, Elsevier Sciences Limited, Edinburgh; 2002. p. 179-190
2. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397-414
3. Manabe N, Wong BS, Camilleri M, et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2009. [Epub ahead of print]
4. Bredenoord AJ, Chiari HJ, Camilleri M, et al. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003;1:264-272
5. Tack J, Jones MP, Karamanolis G, et al. Symptom pattern and pathophysiological correlates of weight loss in tertiary-referred functional dyspepsia. Neurogastroenterol Motil 2010;22:29-35
6. Quartero AO, de Wit NJ, Lodder AC, et al. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998;43:2028-2033
7. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002;71:533-554
8. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000;95:2698-2709
9. Gershon MD. Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004;20:3-14
10. Tonini M, Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006;24:59-69
11. Moro E, Crema F, De Ponti F, Frigo G. Triptans and gastric accommodation: pharmacological and therapeutic aspects. Dig Liver Dis 2004;36:85-92
12. Storr M, Schusdziarra V, Allescher HD. Inhibition of small conductance K +-channels attenuated melatonin-induced relaxation of serotonin-contracted rat gastric fundus. Can J Physiol Pharmacol 2000;78:799-806
13. Hegde SS, Eglen RM. Peripheral 5-HT4 receptors. FASEB J 1996;10:1398-1407
14. Maddern GJ, Jamieson GG, Myers JC, Collins PJ. Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease. Gut 1991;32:470-474
15. Pehlivanov N, Sarosiek I, Whitman R, et al. Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2002;16:743-747
16. Tack J, Broeckaert D, Coulie B, Janssens J. The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther 1998;12:761-766
17. Ruth M, Hamelin B, Röohss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998;12:35-40
18. Kim HS. 5-Hydroxytryptamine4 receptor agonists and colonic motility. J Smooth Muscle Res 2009;45:25-29
19. Kim HS, Choi EJ, Park H. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil 2008;20:169-176
20. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-468 (Pubitemid 30140843)
21. Quigley EM, Wald A, Fidelholtz J, et al. Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies. Clin Gastroenterol Hepatol 2006;4:605-613
22. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007;4:CD003960
23. Ducic I, Ko CM, Shuba Y, et al. Comparative effects of loratadine and terfenadine on cardiac K+ channels. J Cardiovasc Pharmacol 1997;30:42-54
24. Ripden DM. Antiarrhythmic drugs. In: Topol EJ, editor, Comprehensive cardiovascular medicine. Lippincott Raven Publishers, Philadelphia; 1998. p. 2053-2070
25. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-580
26. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269:92-95
27. De Maeyer JH, Lefebvre RA, Schuurkes JAJ. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20:99-112
28. Mohammad S, Zhou Z, Gong Q, January CT. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997;273:H2534-8
29. Nilsson T, Longmore J, Shaw D, et al. Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999;372:49-56
30. MaassenVanDenBrink A, Reekers M, Bax WA, Saxena PR. Human isolated coronary artery contraction to sumatriptan characterized by the selective 5-HT1B/1D receptor antagonist GR55562. Pharmacol Toxicol 2000;86:287-290
31. Villalón CM, Centurión D. Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch 2007;376:45-63
32. Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neuron. Naunyn Schmiedebergs Arch 1989;340:403-410
33. Blondel O, Gastineau M, Dahmoune Y, et al. Cloning, expression and pharmacology of four human 5-hydroxytryptamine4 receptor isoforms produced by alternative splicing in the carboxy terminus. J Neurochem 1998;70:2252-2261
34. Claeysen S, Faye P, Sebben M, et al. 5-HT4 receptors: cloning and expression of new splice variants. Ann NY Acad Sci 1998;861:49-56
35. Sanger GJ. Translating 5-HT receptor pharmacology. Neurogastroenterol Motil 2009;21:1235-1238
36. Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord 2004;3(1):39-51
37. Briejer MR, Akkermans LMA, Schuurkes JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995;47:631-651
38. Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. 5-HT4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 2000;131:927-932
39. Baxter GS, Craig DA, Clarke DE. 5-hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn Schmeidebergs Arch Pharmacol 1991;343:439-446
40. Kilbinger H, Wolf D. Effects of 5-HT4 receptors stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol 1992;345:270-275
41. Kilbinger H, Gebauer A, Haas J, et al. Benzimidazolones and renzapride facilitate acetylcholine release from guinea-pig myenteric plexus via 5-HT4 receptors. Naunyn Schmiedebergs Arch Pharmacol 1995;351:229-236
42. Grider JR, Kuemmerle JF, Jin JG. 5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1P receptors on sensory CGRP neurons. Am J Physiol 1996;270:G778-82
43. Kellum JM, Albuquerque FC, Stoner MC, Harris RP. Stroking human jejunal mucosa induces 5-HT release and Cl-secretion via afferent neurons and 5-HT4 receptors. Am J Physiol 1999;277:G515-20
44. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998;115:370-380
45. Edwards CA, Holden S, Brown C, Read NW. Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects. Gut 1987;28:13-16
46. Krevsky B, Maurer AH, Malmud LS, Fisher RS. Cisapride accelerates colonic transit in constipated patients with colonic inertia. Am J Gastroenterol 1989;84:882-887
47. Krevsky B, Malmud LS, Maurer AH, et al. The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1987;1:293-304
48. Camilleri M, Malagelada JR, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989;96:704-712
49. Camilleri M, Brown ML, Malagelada JR. Impaired transit of chyme in chronic intestinal pseudoobstruction. Correction by cisapride. Gastroenterology 1986;91:619-626
50. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745-1751
51. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354-360
52. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682-686
53. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003;67:82-89
54. Nichols T, Beyens G, Ausma J, et al. A double-blind, placebo-controlled, dose-finding trial on the efficacy and safety of prucalopride in patients with chronic constipation. Gut 2008;57(Suppl II):A283
55. Miner PJ, Nichols T, Silvers D, et al. The efficacy and safety of prucalopride in patients with chronic constipation. Gastroenterology 1999;116:A1043
56. Felt-Bersma R, Bouchoucha M, Wurzer H, et al. Effects of a new enterokinetic drug, prucalopride, on symptoms of patients with chronic constipation: a double-blind, placebo-controlled, multicenter study in Europe. Gastroenterology 1999;116:A1043
57. Winter H, Ausma J, Vandeplassche L. An open label follow-up study of prucalopride solution in pediatric subjects with functional fecal retention. Gastroenterology 2009;116:A1043
58. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-2354
59. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-328
60. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-365
61. Kobert KA, Brattelid T, Levy FO, Kaumann AJ. Prucalopride is a partial agonist through human and porcineatrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants. Naunyn Schmiedebergs Arch Pharmacol 2005;371:473-479
62. De Maeyer J, Straetemans R, Schuurkes J, Lefebvre R. Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development. Br J Pharmacol 2006;147:140-157
63. Bach T, Syversveen T, Kvingedal A, et al. 5 HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Nauuyn Schmiedebergs Arch Pharmacol 2001;363:146-160
64. De Maeyer JH, Schuurkes JA, Lefebvre RA. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br J Pharmacol 2009;156:362-376
65. Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007;554:98-105
66. Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256-e117
67. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16:759-767
68. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16:1347-1356
69. Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007;19:30-38
70. Dennis D, Palme M, Irwin I, et al. ATI-7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dog. Gastroenterology 2004;126:A641
71. Beattie DT, Smith JA, Marquess D, et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol 2004;143:549-560
72. Smith J, Beattie DT, Cuthbert AW, et al. TD-5108, a selective, high intrinsic activity 5-HT4 receptor agonist-in vitro profile at human recombinant 5-HT4 receptor splice variant and human isolated colon. Gastroenterology 2007;132:A687
73. Beattie DT, Armstrong SR, Shaw JP, et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378:139-147
74. Manini ML, Camilleri M, Goldberg M, et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22:42-49, e7-8
75. Goldberg MR, Li YP, Pitzer K, et al. TD-5108, a selective 5-HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 2008;134:A545
76. Goldberg MR, Wong SL, Ganju J, et al. TD-5108, a selective 5-HT4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects. Gastroenterology 2007;132:A60